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Abstract 
The European Association for Neuro-Oncology guideline provides recommendations for the clinical care of 
adult patients with astrocytic and oligodendroglial gliomas, including glioblastomas. The guideline is based on 
the 2016 WHO classification of tumours of the central nervous system and on scientific developments since 
the 2014 guideline. The recommendations focus on pathological and radiological diagnostics, and the main 
treatment modalities of surgery, radiotherapy, and pharmacotherapy. In this guideline we have also 
integrated the results from contemporary clinical trials that have changed clinical practice. The guideline aims 
to provide guidance for diagnostic and management decisions, while limiting unnecessary treatments and 
costs. The recommendations are a resource for professionals involved in the management of patients with 
glioma, for patients and caregivers, and for health-care providers in Europe. The implementation of this 
guideline requires multidisciplinary structures of care, and defined processes of diagnosis and treatment. 
 
Introduction 
 
The European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult 
astrocytic and oligodendroglial gliomas follows the revision of the fourth edition of WHO classification of 
tumours of the central nervous system1 and builds on previous guidelines.2,3 The guideline covers adult 
astrocytic and oligodendroglial gliomas of WHO grades II–IV, including glioblastomas, and variants of these 
tumours, and discusses prevention, early diagnosis and screening, histological and molecular diagnostics, 
therapy, and follow-up. However, the guideline does not address differential diagnosis, adverse effects of 
treatment, or supportive or palliative care. 
 
Diagnostics 
 
Prevention, early diagnosis, and screening 
The annual incidence of gliomas, including glioblastoma, is around six cases per 100 000 individuals 
worldwide. Serum markers for early detection have not been identified. Brain MRI has the highest sensitivity 
for the detection of small tumours. Gliomas can evolve rapidly over several weeks or months, presenting 
challenges for population-based prevention or early intervention. Screening is therefore limited to individuals 
at genetic risk—eg, patients with neurofibromatosis type I, Turcot syndrome, and Li Fraumeni syndrome. 
Repeat scans are not recommended in such individuals unless clinically justified. A particular challenge is the 
counselling and screening of relatives of patients who carry germline mutations associated with 
gliomagenesis, given that prevention strategies are not available.4 
 
History and clinical examination 
The evolution of neurological symptoms and signs enables the growth dynamics of gliomas to be estimated: 
tumours that cause symptoms for weeks are probably fast-growing, whereas tumours that cause symptoms 
for years before being diagnosed are probably slow-growing. Patient history might also reveal familial risk or 
exogenous risk factors, including exposure to radiation or other conditions associated with brain tumours. 
Discussion with relatives might be required to obtain a reliable history. Characteristics of clinical presentation 
are new onset epilepsy, focal deficits, including neurocognitive impairment, and indicators of intracranial 
mass effect, such as headache, vomiting, and altered consciousness. Physical examination focuses on the 
detection of systemic cancer and contraindications for neurosurgical procedures. Neurocognitive assessment 
beyond documenting the Karnofsky performance score or the WHO performance status, and the performance 
of a Mini-Mental State Examination5 or a Montreal Cognitive Assessment,6 has become increasingly 
common.7,8 The Mini-Mental State Examination is widely used as a screening tool across Europe and remains 
freely available for individual use—eg, outside of clinical trials. 
 
Ancillary studies 
MRI, including T2-weighted and fluid-attenuated inversion recovery sequences, and T1-weighted sequences 
before and after gadolinium use, in at least one plane, is the standard method for the detection of a 
glioma.9 Additionally, cranial CT shows calcifications, intra-arterial angiography can aid the surgical strategy, 
and aminoacid PET helps define metabolic hotspots for biopsy.10 Standardised MRI sequences are also 
recommended to assess the efficacy of therapeutic interventions.11 Cerebrospinal fluid studies have no major 
role in the diagnostic work-up of gliomas and lumbar punctures carry the risk of neurological deterioration in 
patients with large space-occupying tumours. Electroencephalography is useful for monitoring tumour-
associated epilepsy and in determining causes of altered consciousness. 
 
Preoperative management 
Management should follow documented local standard operating procedures and multidisciplinary discussion 
in a brain tumour board review that ideally should include dedicated neuroradiologists and neuropathologists, 
in addition to neurosurgeons, radiation oncologists, and neurooncologists. Before surgery, unless 
contraindications are present or primary cerebral lymphoma or inflammatory lesions are suspected, 
corticosteroids should be administered to decrease tumour-associated oedema. Additional pharmacological 
interventions, such as osmotic drugs, are rarely necessary. Patients with glioma who have epileptic seizures 
should receive anticonvulsant drugs preoperatively; however, evidence shows that primary prophylaxis does 
not reduce the risk of a first seizure in patients with glioma without a history of seizures.12 
 
Biopsy or resection 
Treatment decisions in patients with glioma are dependent on tissue diagnosis and the assessment of selected 
molecular markers. Thus, surgery is commonly performed with diagnostic and therapeutic objectives. The 
surgical management of patients with glioma should take place in high-volume specialist centres, where high-
volume refers to the high volume of patients individual surgeons specifically treat.13 A decision to initiate 
palliative care without histological diagnosis should be avoided unless the risk of the biopsy is considered too 
high or the prognosis is likely to be unfavourable even with treatment—eg, in patients with large tumours 
who are at risk of rapid clinical decline. Stereotactic biopsies under local anaesthesia are associated with low 
morbidity14 and an integrated diagnosis can be used to counsel patients and relatives even when no further 
tumour-specific therapy is recommended. Serial samples from the tumour mass along the trajectory of the 
biopsy needle should be acquired during the stereotactic procedure, which requires an experienced team of 
neurosurgeons and neuropathologists. 
 
Histological classification and molecular diagnostics 
Intraoperative assessment of cytological specimens or frozen sections before the surgical procedure is 
terminated helps to ensure that sufficient tissue is obtained to establish a diagnosis. Tumour tissue is 
formalin-fixed and embedded in paraffin for conventional histological staining, including routine 
haematoxylin-eosin staining and additional immunohistochemical and molecular analyses. If possible, part of 
the tissue should be cryopreserved for future molecular marker studies. The diagnostic process follows the 
WHO classification1 and integrates histological tumour typing, tumour grading using the four-tiered WHO 
grading scheme (WHO grade I–IV)—designed to provide clinicians with information about the biological 
behaviour of tumours and consequently the patient's prognosis and outcome—and tissue-based molecular 
biomarkers (figure 1). The 2016 WHO classification1specifies the major diagnostic role of isocitrate 
dehydrogenase 1 (IDH1) codon 132 or IDH2codon 172 missense mutations and defines diffuse and anaplastic 
astrocytic gliomas and oligodendroglial gliomas as IDH-mutant tumours.1 
 
 
 
Figure 1. Diagnostic algorithm for integrated classification of diffuse astrocytic and oligodendroglial gliomas, 
including glioblastoma 
 
 
Oligodendroglial tumours also have 1p/19q codeletions. IDH-wild-type diffuse astrocytomas and anaplastic 
astrocytomas are considered provisional entities. Not otherwise specified categories have been introduced for 
gliomas and are defined as those that cannot be tested for the diagnostically relevant markers, or for which 
testing remains inconclusive. Table 1 shows the management recommendations for these not otherwise 
specified categories, but evidence on how to manage these tumours best is scarce. Oligoastrocytomas and 
gliomatosis cerebri do not have distinctive genetic and epigenetic profiles24,25 and thus are not considered 
distinct glioma entities.1 Diffuse midline glioma, histone H3-K27M-mutant, has been introduced as a new 
entity characterised by midline tumour location and the presence of a mutation at codon 27 that results in a 
lysine to methionine change in histones H3·3 or H3·1.1 
 
  
Table 1. Key treatment recommendations for patients with diffuse astrocytic and oligodendroglial tumours according to the new WHO classification1 
 
 First-line treatment* Salvage therapies†‡ Comments and references 
Diffuse astrocytic and oligodendroglial tumours 
Diffuse astrocytoma, IDH-mutant Watch-and-wait or radiotherapy followed by PCV (or 
temozolomide plus radiotherapy followed by temozolomide) 
Nitrosourea (or temozolomide 
rechallenge or bevacizumab§) 
RTOG 9802 trial15 and extrapolation from 
WHO grade III tumours16 
Gemistocytic astrocytoma, IDH-mutant Watch-and-wait or radiotherapy followed by PCV (or 
temozolomide plus radiotherapy followed by temozolomide) 
Nitrosourea (or temozolomide 
rechallenge or bevacizumab§) 
.. 
Diffuse astrocytoma, IDH-wild-type Watch-and-wait (remains controversial), radiotherapy, 
radiotherapy followed by PCV, or temozolomide and 
radiotherapy followed by temozolomide (according 
to MGMT status [remains controversial]) 
Temozolomide, or nitrosourea (or 
temozolomide rechallenge) or 
bevacizumab§ 
Extrapolation from IDH-wild-type 
glioblastoma17 
Diffuse astrocytoma, not otherwise 
specified 
Watch-and-wait or radiotherapy followed by PCV (or 
temozolomide plus radiotherapy followed by temozolomide) 
Nitrosourea (or temozolomide 
rechallenge or bevacizumab§) 
.. 
Anaplastic astrocytoma, IDH-mutant Radiotherapy followed by temozolomide Nitrosourea or temozolomide 
rechallenge or bevacizumab§ 
16 
Anaplastic astrocytoma, IDH-wild-type Radiotherapy or temozolomide plus radiotherapy followed 
by temozolomide, according to MGMT status (remains 
controversial) 
Temozolomide, or nitrosourea (or 
temozolomide rechallenge) or 
bevacizumab§ 
Extrapolation from IDH-wild-type 
glioblastoma17,18 
Anaplastic astrocytoma, not otherwise 
specified 
Radiotherapy followed by temozolomide and radiotherapy 
followed by temozolomide, according to MGMT status 
(remains controversial) 
Nitrosourea or temozolomide 
rechallenge or bevacizumab§ 
.. 
Glioblastoma, IDH-wild-type (including 
giant cell glioblastoma, gliosarcoma, 
and epithelioid glioblastoma) 
Temozolomide plus radiotherapy followed by temozolomide 
for patients aged 70 years or younger; radiotherapy alone 
(MGMT unmethylated) or temozolomide plus radiotherapy 
followed by temozolomide or temozolomide alone 
(MGMTmethylated) for patients older than 70 years 
Nitrosourea or temozolomide 
rechallenge or bevacizumab§, 
radiotherapy for radiotherapy-
naive patients 
17,19–21 
Glioblastoma, IDH-mutant Radiotherapy with or without temozolomide followed by 
temozolomide 
Nitrosourea or temozolomide 
rechallenge or bevacizumab§ 
Extrapolation from IDH-mutant 
anaplastic astrocytoma16 
Glioblastoma, not otherwise specified Temozolomide plus radiotherapy followed by temozolomide 
for patients aged 70 years or younger; radiotherapy alone 
(MGMT unmethylated) or temozolomide plus radiotherapy 
Nitrosourea or temozolomide 
rechallenge or bevacizumab§, 
radiotherapy for radiotherapy-
naive patients 
17 
 First-line treatment* Salvage therapies†‡ Comments and references 
followed by temozolomide or temozolomide alone 
(MGMTmethylated) for patients older than 70 years 
Diffuse midline glioma, H3-K27M 
mutant 
Radiotherapy or temozolomide plus radiotherapy followed 
by temozolomide 
.. .. 
Oligodendroglioma, IDH-mutant and 
1p/19q-codeleted 
Watch-and-wait or radiotherapy followed by PCV Temozolomide or bevacizumab§ Extrapolation from WHO grade III 
tumours22,23and RTOG 9802 trial15 
Oligodendroglioma, not otherwise 
specified 
Watch-and-wait or radiotherapy followed by PCV Temozolomide or bevacizumab§ Extrapolation from WHO grade III 
tumours22,23and RTOG 9802 trial15 
Anaplastic oligodendroglioma, IDH-
mutant and 1p/19q-codeleted 
Radiotherapy followed by PCV Temozolomide or bevacizumab§ 22,23 
Anaplastic oligodendroglioma, not 
otherwise specified 
Radiotherapy followed by PCV Temozolomide or bevacizumab§ 22,23 
Oligoastrocytoma, not otherwise 
specified 
Watch-and-wait or radiotherapy followed by PCV Temozolomide or bevacizumab§ Extrapolation from WHO grade III 
tumours22,23and RTOG 9802 trial15 
Anaplastic oligoastrocytoma, not 
otherwise specified 
Radiotherapy followed by PCV Temozolomide or bevacizumab§ 22,23 
Other astrocytic tumours 
Pilocytic astrocytoma  
Pilomyxoid astrocytoma 
Surgery only Surgery followed by radiotherapy .. 
Subependymal giant cell astrocytoma Surgery only Surgery .. 
Pleomorphic xanthoastrocytoma Surgery only Surgery .. 
Anaplastic pleomorphic 
xanthoastrocytoma 
Radiotherapy Surgery followed by 
chemotherapy with temozolomide 
.. 
 
IDH=isocitrate dehydrogenase. PCV=procarbazine, lomustine, and vincristine. RTOG=Radiation Therapy Oncology Group. MGMT=O6-methylguanine DNA methyltransferase. H3=histone 3. 
* Maximum safe resection is recommended whenever feasible in all patients with newly diagnosed gliomas. 
† Second surgery should always be considered, but clinical benefit may be limited to patients where a gross total resection can be achieved. 
‡ Re-exposure to temozolomide and less so nitrosourea treatment has little activity in tumours without MGMT promoter methylation. 
§ Depending on local availability. 
Four molecular biomarkers are central to diagnosing and treating gliomas: IDH mutation, 1p/19q codeletion, 
histone H3-K27M mutation, and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation. 
IDH mutation, 1p/19q codeletion, and histone H3-K27M mutation have been incorporated into the revised 
WHO tumour classification (table 1), whereas MGMT promoter methylation status guides treatment decisions 
about chemotherapy use.26MGMT promoter methylation status should be tested by the use of molecular 
genetic tests, such as methylation-specific PCR or pyrosequencing of bisulphite-modified tumour DNA, 
whereas immunocytochemistry is not an adequate method to establish the MGMT status. 
Immunohistochemical detection of loss of nuclear ATRX expression in IDH-mutant gliomas is characteristic of 
astrocytic gliomas without 1p/19q codeletion. Thus, additional testing for 1p/19q codeletion might not be 
required in such cases, unless doubts exist regarding astrocytic differentiation or the validity of ATRX 
immunohistochemistry. By contrast, retention of nuclear ATRX expression in an IDH-mutant glioma should 
prompt testing for the 1p/19q codeletion to differentiate an IDH-mutant astrocytic glioma from an IDH-
mutant and 1p/19q-codeleted oligodendroglial tumour. Thus, ATRX immunohistochemistry might facilitate 
diagnostic categorisation of IDH-mutant gliomas but is not a substitute for 1p/19q codeletion testing. 
Similarly, detection of mutations in the telomerase reverse transcriptase (TERT) promoter cannot substitute 
for 1p/19q codeletion testing because TERT promoter mutations are not restricted to IDH-mutant and 
1p/19q-codeleted oligodendroglial tumours, but also occur in a minor subset of IDH-mutant astrocytic gliomas 
and most IDH-wild-type glioblastomas. High-throughput assays based on next generation sequencing or 
microarray techniques might soon replace single marker assessments. Diagnostic algorithms for patients with 
glioma should be standardised and should not delay radiotherapy or tumour-specific pharmacotherapy. 
 
Figure 1 shows a commonly used approach for differential diagnostic work-up after histological analysis: the 
tumours are assessed by immunohistochemistry for the IDH1-R132H mutation and loss of nuclear ATRX 
protein expression. In the case of diffuse gliomas located in midline structures (thalamus, brain stem, and 
spinal cord), immunostaining for the histone H3-K27M mutation characterises diffuse midline glioma, histone 
H3-K27M-mutant. After immunohistochemistry, molecular analyses for less common IDH1 codon 132 
mutations (other than R132H), or IDH2 codon 172 mutations (eg, by DNA sequencing), and for codeletion of 
chromosomal arms 1p and 19q (eg, by fluorescent in-situ hybridisation or microsatellite PCR-based loss of 
heterozygosity analyses) are done according to the individual immunohistochemistry results. IDH mutation 
and loss of nuclear ATRX expression classify IDH-mutant astrocytic gliomas (figure 1). Additional molecular 
testing for 1p/19q codeletion is not routinely required but might be performed to further substantiate the 
diagnosis (eg, in cases with ambigous histology). In patients older than 55 years at diagnosis, with a 
histologically typical glioblastoma, without a pre-existing lower grade glioma and with non-midline tumour 
location, immunohistochemical negativity for IDH1-R132H expression is sufficient for classification as 
glioblastoma, IDH-wild-type (figure 1). In all other diffuse gliomas, absence of IDH1-R132H immunopositivity 
should be followed by IDH1 and IDH2 sequencing to detect or exclude other, less common IDH mutations. 
IDH-wild-type diffuse astrocytic gliomas with loss of nuclear ATRX expression may be additionally tested for 
histone H3 mutations (figure 1). 
 
General recommendations for therapy 
 
Prognostic factors 
Younger age and better performance status are important positive, therapy-independent prognostic factors 
across glioma entities, and extent of resection is an important therapy-dependent prognostic factor (figure 2). 
Molecular markers that favour longer survival, such as IDH mutation and 1p/19q codeletion, are now at the 
core of the WHO classification and define more homogeneous diagnostic and prognostic entities.1,26 
 
 
 
Figure 2. Clinical pathway for glioma 
 
 
Maximum safe resection is recommended whenever feasible in all patients with newly diagnosed gliomas. 
IDH=isocitrate dehydrogenase. KPS=Karnofsky performance score. MGMT=O6-methylguanine DNA 
methyltransferase. PCV=procarbazine, lomustine, and vincristine. 
 
  
Surgical therapy 
Beyond a histological diagnosis, the goal of surgery is to remove as much of the tumour as safely possible to 
improve neurological function. Microsurgical techniques are standard. The use of several tools, including 
surgical navigation systems with functional MRI datasets, intraoperative MRI, ultrasound, intraoperative 
functional monitoring and the fluorescent dye 5-aminolevulinic acid to visualise tumour tissue,27 is becoming 
more frequent in order to increase the extent of resection, while minimising the risk of new neurological 
deficits.28 The use of evoked potentials (electrical activity in the brain following an external stimulus), 
electromyography, or mapping in conscious patients under local anaesthesia to monitor and preserve 
language and cognition, should support resections in eloquent areas (ie, areas of the brain that cannot be 
removed without causing permanent neurological deficits, such as the cortex and subcortical white matter). 
The prevention of new, permanent neurological deficits is more important than extent of resection as gliomas 
are not cured by surgery, because tumour cells infiltrate far beyond the lesion and demonstrate network-like 
growth, both of which are hallmarks of diffuse gliomas.29 Postoperative deficits due to emerging 
complications are a negative prognostic factor. Furthermore, quality of life is a high priority to patients and 
carers. The result of surgery is assessed by early MRI—or CT if MRI is not possible—with and without contrast 
and diffusion imaging within 24–72 h of surgery, which is part of the standard of care.30 A large residual 
tumour volume after surgery is a negative prognostic factor, but it remains uncertain whether extent of 
resection truly matters, or whether resectable tumours have a different biology associated with a less 
aggressive course of disease. 
 
Radiotherapy 
The goal of radiotherapy for patients with gliomas is to improve local control at a reasonable risk benefit ratio. 
Radiotherapy helps to preserve function and increases survival. Indications for timing, dosing, and scheduling 
of radiotherapy are determined by diagnosis and prognostic factors, including age, Karnofsky performance 
score, and extent of resection.31 Focal radiotherapy is administered at 50–60 Gy in 1·8–2·0 Gy fractions, 
depending on prognosis defined by tumour type and grade. Hypofractionated radiotherapy with higher 
fractions and a lower total dose (eg, 15 × 2·67 Gy) is appropriate in older patients and individuals with poor 
prognostic factors. The area of residual enhancement on T1 MRI imaging plus the surgical bed is defined as 
the gross tumour volume. A margin, typically 1·0–1·5 to 2·5 cm including the hyperintensity on T2 or fluid-
attenuated inversion recovery imaging, is added to the gross tumour volume to define the clinical target 
volume. This clinical target volume is then modified to take into account areas in which microscopic spread is 
unlikely, or to reduce the radiotherapy dose to vital structures. Another margin, usually 0·3–0·5 cm, is added 
to the clinical target volume to allow for error setup and movement during treatment, to generate the 
planning target volume.32 PET is being studied for improving target delineation in clinical trials.10 
 
Organs at high risk of radiotherapy-associated toxicity, including optic nerves, optic chiasm, retinas, lenses, 
brainstem, pituitary, cochleas, and the hippocampus should be determined. Modern techniques of focused 
radiotherapy—eg, intensity-modulated or image-guided radiotherapy in patients with newly diagnosed 
glioma, and stereotactic radiotherapy in the recurrent setting—might improve the targeted delivery of 
radiotherapy to better protect surrounding tissue. In children especially, but also in adults with deeply 
localised tumours, interstitial brachytherapy and proton or heavy ion radiotherapy might be alternatives. 
Randomised data comparing novel approaches with standard techniques are not available. 
 
Pharmacotherapy 
Cytotoxic chemotherapy is part of the standard of care for most patients with glioma (panel; figure 3). This 
treatment requires regular haematological, hepatic, and renal laboratory tests and exclusion of major lung 
disease or heart disease and infection. Additionally, blood counts need to be monitored during therapy. 
Temozolomide, an oral DNA alkylating agent with good blood–brain barrier penetration, is widely used in 
glioma treatment and has a favourable safety profile, with myelosuppression, notably thrombocytopenia, as 
the main and dose-limiting toxicity of the drug. Hepatic function should also be assessed regularly. By contrast 
with temozolomide, nitrosoureas, such as lomustine, carmustine, nimustine, and fotemustine, cause 
prolonged leukopenia and thrombocytopenia. These toxic effects might necessitate delays to further 
treatment at reduced dose or even discontinuation and consideration of alternative treatments. Pulmonary 
fibrosis is probably most often seen with carmustine when compared with other nitrosoureas.33  
Nitrosoureas have become a second choice after temozolomide for glioma treatment in most European 
countries, although no data from large comparative trials are available and retrospective or subgroup 
analyses suggest a higher efficacy of procarbazine, lomustine, and vincristine over temozolomide in patients 
with anaplastic glioma with a good prognosis.34,35 Locally delivered carmustine wafers that are implanted into 
the surgical cavity have provided a modest survival advantage to patients with newly diagnosed WHO grade III 
or IV gliomas, or recurrent glioblastoma,36 but are now a rarely considered option because of poor efficacy 
and concerns about safety when combined with newer treatments such as temozolomide, and are used 
mostly in patients without systemic treatment options. Application of carmustine wafers requires careful 
patient selection and a gross total resection. Of the various candidate anti-angiogenic drugs investigated in 
clinical trials in glioma patients, only bevacizumab, an antibody to vascular endothelial growth factor, is 
approved for recurrent glioblastoma in the USA, Canada, Switzerland, and several other countries outside the 
European Union. Despite extensive efforts, no single biomarker in tumour tissue or plasma has been shown to 
predict benefit from or resistance to bevacizumab in independent datasets. Patients with glioma undergoing 
systemic therapy should have their treatment documented in print or electronically, including laboratory 
results and information on complications and contraindications. Clinical centres that manage patients with 
glioma should generate standard operating procedures and instructions for handling side-effects and 
complications from treatment. 
 
  
Panel: Dose and mode of administration of chemotherapy protocols in malignant glioma 
Temozolomide 
• 75 mg/m2 orally, daily including weekends during radiotherapy 
• 150–200 mg/m2 orally, days 1–5, fasting in the morning every 4 weeks for six cycles of maintenance 
treatment 
Nimustine, carmustine, lomustine, and fotemustine 
• Different regimens, most commonly lomustine 110 mg/m2 orally every 6 weeks 
Procarbazine, loumustine, and vincristine 
• Procarbazine 60 mg/m2 orally, days 8–21 
• Lomustine 110 mg/m2 orally, day 1 
• Vincristine 1·4 mg/m2 intravenously (maximum 2 mg), days 8 and 29 for 6–8 weeks 
Bevacizumab 
• 10 mg/m2 once every 2 weeks 
 
 
 
 
 
Figure 3. Therapeutic approaches to diffuse astrocytic or oligodendroglial gliomas in adulthood 
Supportive care is an option across the entities, but has been omitted for clarity. IDH=isocitrate 
dehydrogenase. PCV=procarbazine, lomustine, and vincristine. 
 
 
Other therapeutic approaches 
Other approaches to glioma therapy, including various targeted and immunological therapies, notably 
immune checkpoint inhibitors and vaccines, are of unknown efficacy and should be explored within clinical 
trials. 
Monitoring and follow-up 
In addition to clinical examination, MRI is the standard diagnostic measure for the evaluation of disease status 
or treatment response. 3-month intervals for MRI and follow-up visits are common practice initially in most 
patients, but longer intervals are appropriate in cases of durable disease control and less aggressive tumours 
(figure 2). In cases of suspected disease progression, an earlier MRI after 4–6 weeks might be reasonable to 
confirm progression. Pseudoprogression and pseudoresponse are most likely to occur during the first 3 
months of treatment. Particular attention is needed when interpreting scans during this period, and 
rescanning after shorter intervals is a pragmatic approach in case of doubt. Perfusion MRI and aminoacid PET 
can help to distinguish pseudoprogression from progression. Biopsies are not uniformly informative because 
viable tumour cells are regularly detected even in patients with pseudoprogression. To address the risk of 
pseudoresponse, the Response Assessment in Neuro-Oncology working group has recommended that 
assessment of non-contrast-enhancing tumour components should be an additional key constituent of 
response criteria.11 Preliminary evidence shows that lower grade gliomas might exhibit accelerated growth 
during pregnancy.37 MRI without gadolinium should be used as a safe approach to assess disease activity 
during pregnancy if considered necessary. 
 
Table 2 shows the key recommendations of the EANO task force 39 
 
Class of 
evidence 
Level of 
recommendation 
General 
Karnofsky performance score, neurological function, age, and individual risks and 
benefits should be considered for clinical decision making. 
I A 
Screening and prevention have no major role for patients with gliomas. IV .. 
Patients with germ line variants or suspected hereditary cancer syndromes should 
receive genetic counselling and subsequently might be referred for molecular genetic 
testing. 
IV .. 
First choice diagnostic imaging approach is MRI with and without contrast 
enhancement. 
IV .. 
Pseudoprogression should be considered in patients with an increase in tumour 
volume on neuroimaging in the first months after local therapeutic interventions, 
including radiotherapy and experimental local treatments. 
II B 
Clinical decision making without obtaining a definitive WHO diagnosis at least by 
biopsy should occur only in exceptional situations. 
IV .. 
Glioma classification should follow the new WHO classification of tumours of the 
central nervous system 2016. 
IV .. 
Immunohistochemistry for mutant IDH1-R132H protein and nuclear expression of 
ATRX should be performed routinely in the diagnostic assessment of gliomas. 
IV .. 
IDH mutation status should be assessed by immunohistochemistry for IDH1-R132H. If 
negative, immunohistochemistry should be followed by sequencing of IDH1 codon 
132 and IDH2 codon 172 in all WHO grade II and III astrocytic and oligodendroglial 
gliomas and in all glioblastomas of patients younger than 55 years to allow for 
integrated diagnoses according to the WHO classification and to guide treatment 
decisions. 
IV .. 
 
Class of 
evidence 
Level of 
recommendation 
1p/19q codeletion status should be determined in all IDH-mutant gliomas with 
retained nuclear expression of ATRX. 
II B 
MGMT promoter methylation status should be determined in elderly patients with 
glioblastoma and in IDH-wild-type WHO grade II and III gliomas to guide decision for 
the use of temozolomide instead of or in addition to radiotherapy. 
I B 
Residual tumour volume after surgery is a prognostic factor, therefore efforts to 
obtain complete resections are justified across all glioma entities. 
IV .. 
Prevention of new permanent neurological deficits has higher priority than extent of 
resection in the current surgical approach to gliomas. 
IV .. 
IDH-mutant gliomas (WHO grade II or II) 
Standard of care for WHO grade II astrocytomas (1p/19q-non-codeleted) that require 
further treatment includes resection, as feasible, or biopsy followed by involved field 
radiotherapy and maintenance procarbazine, lomustine, and vincristine 
chemotherapy (RTOG 9802 trial).15 
II B 
Standard of care for 1p/19q-non-codeleted anaplastic astrocytoma includes 
resection, as feasible, or biopsy followed by involved field radiotherapy and 
maintenance temozolomide.16 
II B 
Patients with 1p/19q-codeleted WHO grade II oligodendroglial tumours requiring 
further treatment should be treated with radiotherapy plus procarbazine, lomustine, 
and vincristine chemotherapy. 
III B 
Patients with 1p/19q-codeleted anaplastic oligodendroglial tumours should be 
treated with radiotherapy plus procarbazine, lomustine, and vincristine 
chemotherapy (EORTC 26951 and RTOG 9402 trials).22,23 
II B 
Temozolomide chemotherapy is standard treatment at progression after surgery and 
radiotherapy for most patients with WHO grade II and III gliomas. 
II B 
Glioblastoma, IDH-wild-type (WHO grade IV) 
Standard of care for glioblastoma, IDH-wild-type (age <70 years, Karnofsky 
performance score ≥70) includes resection as feasible or biopsy followed by involved-
field radiotherapy and 6 cycles of concomitant and maintenance temozolomide 
chemotherapy (EORTC 26981 NCIC CE.3 trial).17 
I A 
Temozolomide is particularly active in patients with MGMT promoter methylation 
whereas its activity in patients with MGMT promoter-unmethylated tumours is 
marginal.38 
II B 
Elderly patients not considered candidates for concomitant or maintenance 
temozolomide plus radiotherapy should be treated based on MGMT promoter 
methylation status (Nordic,19 NOA-08,20 and NCIC CE.6 EORTC 606221 trials) with 
radiotherapy (eg, 15 × 2·66 Gy) or temozolomide (5 out of 28 days). 
II B 
Standards of care are not well defined at recurrence. Nitrosourea regimens, 
temozolomide rechallenge and, with consideration of the country-specific label, 
bevacizumab are pharmacological options, but an effect on overall survival remains 
unproven. When available, recruitment into appropriate clinical trials should be 
considered. 
II B 
IDH=isocitrate dehydrogenase. MGMT=O6-methylguanine DNA methyltransferase. RTOG=Radiation Therapy Oncology 
Group. EORTC=European Organisation for Research and Treatment of Cancer. NCIC=National Cancer Institute of Canada. 
 
Diffuse astrocytoma 
Diffuse astrocytomas, IDH-mutant, are the most common WHO grade II astrocytomas. Gemistocytic 
astrocytomas are a variant of IDH-mutant diffuse astrocytoma characterised by the presence of gemistocytic 
neoplastic astrocyctes, which should account for at least 20% of all tumour cells.1 Maximum surgical 
resection, as feasible, is increasingly considered the best initial therapeutic measure. Watch-and-wait 
strategies without establishment of a histology-based diagnosis are less commonly pursued, even for patients 
with incidentally discovered lesions. Younger patients (pragmatic cutoff 40–45 years) with seizures only 
should be managed by observation alone only after gross total resection. Involved field radiotherapy (50 Gy), 
which prolongs progression-free survival, but not overall survival, should be considered for patients with 
incomplete resection or patients older than 40 years.40 Chemotherapy alone as initial treatment should be 
considered investigational, but might be an option in patients with extensive tumours, although progression-
free survival is probably shorter with temozolomide than with radiotherapy.41 The Radiation Therapy 
Oncology Group 9802 trial15 in patients with high-risk WHO grade II gliomas who were 18–39 years of age and 
had undergone a subtotal resection or biopsy, or who were aged 40 years or older compared 
chemoradiotherapy to radiotherapy alone. The trial reported that the addition of procarbazine, lomustine, 
and vincristine chemotherapy to radiotherapy (54 Gy) resulted in an overall survival of 13·3 years compared 
with 7·8 years in patients who received radiotherapy alone. Radiotherapy followed by procarbazine, 
lomustine, and vincristine constitutes a new standard of care, in view of the absence of other upcoming 
clinical trial results that are likely to challenge these data. The Radiation Therapy Oncology Group 9802 trial 
reported that longer overall survival in patients treated with chemoradiotherapy was noted across histological 
subgroups and, although data are scarce, there was no association between benefit from chemotherapy and 
any biomarker, however the study was not powered to evaluate these differences.15 Treatment at progression 
depends on neurological status, patterns of progression, and first-line therapy. Second surgery should always 
be considered, usually followed by radiotherapy in previously non-irradiated patients or chemotherapy with 
alkylating drugs. Temozolomide is often preferred over procarbazine, lomustine, and vincristine 
chemotherapy because of its favourable safety profile and ease of administration. IDH-wild-type diffuse 
astrocytomas can have an aggressive course, resembling glioblastoma, especially in elderly patients, but there 
are less aggressive variants.42 
 
Anaplastic astrocytoma 
Anaplastic astrocytomas, IDH-mutant, are the most common WHO grade III astrocytomas. Standard 
treatment includes maximal surgical removal or biopsy followed by radiotherapy at 60 Gy in 1.8–2·0 Gy 
fractions (table 1), with doses based on trials in which these tumours were pooled with glioblastomas. The 
NOA-04 trial35,43 showed that procarbazine, lomustine, and vincristine chemotherapy or temozolomide alone 
were as effective as radiotherapy alone for progression-free survival and overall survival. The European 
Organisation for Research and Treatment of Cancer (EORTC) 26053 trial (CATNON)16 explored whether the 
addition of concomitant temozolomide or maintenance temozolomide to radiotherapy improved outcome 
compared with radiotherapy alone in patients with newly diagnosed 1p/19q-non-codeleted anaplastic 
gliomas in a 2 × 2 factorial trial design. An interim analysis suggested that patients treated with 12 cycles of 
maintenance temozolomide had longer overall survival than patients not treated with maintenance 
temozolomide. Maintenance temozolomide has since been introduced as the standard of care, whereas the 
value of concomitant temozolomide remains unclear.16 Molecular marker studies in the CATNON trial are 
pending. A retrospective study18 of pooled datasets indicated that patients with IDH-wild-type tumours 
and MGMT promoter methylation benefit specifically from chemotherapy with alkylating drugs. 
 
First-line therapy informs treatment choices in patients with recurrent disease. An indication for second 
surgery should be explored. In patients who relapse after radiotherapy, re-irradiation is an option, with a 
minimum interval of 12 months from first radiotherapy course. However, the extent and patterns of 
recurrence restrict the options of radiotherapy in second line treatment, and the overall efficacy remains 
uncertain because data from randomised trials are scarce. Chemotherapy with alkylating drugs should be 
considered for chemonaive patients who progress after radiotherapy, with temozolomide and nitrosoureas 
considered to be equally effective in second line treatment.44,45 Bevacizumab is also an option used after 
relapse following radiotherapy and chemotherapy, with progression-free survival at 6 months reported to be 
between 20–60%.46,47 However, controlled data, including those for combined treatment with bevacizumab 
and chemotherapy, are scarce. 
 
Glioblastoma 
Most histological glioblastomas are IDH-wild-type, including the morphological variants of giant cell 
glioblastoma, gliosarcoma, and epithelioid glioblastoma. To date, no specific treatment recommendations for 
glioblastoma variants exist. About 50% of the rare epithelioid glioblastomas have a 
targetable BRAFV600E mutation, but the promising activity of BRAF inhibitors in this setting remains to be 
evaluated systematically. IDH-mutant glioblastomas are increasingly treated in the same way as IDH-mutant 
anaplastic astrocytoma. 
 
Surgery for IDH-wild-type glioblastoma should be gross total resection when feasible. A small randomised 
trial48 in patients older than 65 years at diagnosis with WHO grade III or IV glioma reported longer overall 
survival in patients treated with resection compared with those who had a biopsy, but the results remain 
controversial because of the small sample size and Karnofsky performance score imbalances between groups. 
Although some studies49,50 reported gradual improvement in outcome with increasing extent of resection, 
only gross total resection might be associated with improved outcome. 
 
Radiotherapy has been the standard of care for glioblastoma since the 1980s, roughly doubling 
survival.31,51 The standard dose is 60 Gy in 1·8–2·0 Gy fractions; 50 Gy in 1·8 Gy fractions improved survival 
relative to best supportive care in patients 70 years or older with good Karnofsky performance 
scores.52 Patients with unfavourable prognostic factors, defined by age or Karnofsky performance score, are 
treated with hypofractionated radiotherapy (eg, 40 Gy in 15 fractions), which had similar efficacy to 60 Gy in 
30 fractions in a randomised phase II trial.53 In elderly patients (aged >70 years), hypofractionated 
radiotherapy is the standard treatment for those with tumours without MGMT promoter 
methylation.19,20 Further hypofractionation to 5  fractions of  5 Gy might be feasible without compromising 
survival,54 but is unlikely to be well-tolerated in terms of neurocognitive side-effects, which could become 
especially important once other treatment options allow long-term survival in elderly glioblastoma patients. 
Accelerated hyperfractionated regimens, accelerated hypofractionated regimens, brachytherapy, 
radiosurgery, and stereotactic radiotherapy boosts confer no survival advantage compared with standard 
regimens.32 
 
Concomitant and maintenance temozolomide chemotherapy plus radiotherapy is the standard of care for 
newly diagnosed adult patients in good general and neurological condition, aged up to 70 years.17,55,56 A 
National Cancer Institute of Canada CE.6 EORTC 26062 trial21 enrolled patients with newly diagnosed 
glioblastoma (aged ≥65 years) to examine the addition of concomitant and maintenance temozolomide to 
radiotherapy (40 Gy in 15 fractions) and reported longer overall survival in patients treated with concomitant 
and maintenance temozolomide and radiotherapy compared with patients treated with radiotherapy alone. 
Thus, no indication exists that the benefit from temozolomide is reduced with increasing age.21 
 
The benefit of temozolomide is most obvious in patients with MGMT promoter-methylated 
glioblastoma.21,38 The Nordic trial19 and NOA-0820 trial resulted in the introduction of MGMT promoter 
methylation testing as standard practice in many European countries in elderly patients not eligible for 
combined modality treatment: patients with tumours without MGMT promoter methylation should be 
treated with hypofractionated radiotherapy alone. Hypofractionated radiotherapy is also the treatment of 
choice for elderly patients when the MGMT status is unknown. Patients with tumours with MGMT promoter 
methylation should receive temozolomide alone (5 of 28 days) until progression or for 12 months. 
 
Trials57–59 in patients without MGMT promoter methylation showed that the omission of temozolomide from 
first-line standard of care treatment was of no detriment to patients, challenging the view that temozolomide 
should be used in every patient despite the absence of MGMT promoter methylation. This concept is 
particularly relevant for elderly or frail patients who might be less tolerant of combined modality treatment. 
 
An increased dose of temozolomide is of no benefit in newly diagnosed patients60 and the extension of 
chemotherapy duration beyond six cycles is probably also of no benefit.61,62 
 
Supportive and palliative care are appropriate for patients with large or multifocal lesions with a low 
Karnofsky performance score, especially if patients are unable to consent to further therapy after biopsy. 
Local carmustine wafer chemotherapy combined with radiotherapy conferred longer survival from first-line 
treatment compared with patients treated with radiotherapy alone (13·9 vs 11·6 months) for an intention-to-
treat population of patients with high-grade glioma, but clinical outcomes did not differ significantly when 
only patients with glioblastoma were considered.36,56,63 However, clinical outcomes differed significantly in 
patients with glioblastoma who underwent a larger than 90% resection.64 
 
Two randomised trials65,66 done in adult patients with glioblastoma noted that progression-free survival was 
longer by 3–4 months in patients treated with bevacizumab in addition to concomitant and maintentance 
temozolomide chemotherapy and radiotherapy compared with patients treated with concomitant and 
maintenance temozolomide chemotherapy and radiotherapy alone. However, the addition of bevacizumab to 
this regimen did not affect overall survival compared with concomitant and maintenance temozolomide 
chemotherapy and radiotherapy alone. However, the clinical significance of increased progression-free 
survival reported in these trials65,66 has been disputed because the reliability of neuroimaging for the 
assessment of progression is unclear and the RTOG 0825 trial65 raised concerns of early cognitive decline in 
patients treated with bevacizumab. On the basis of these data, bevacizumab has not been approved for newly 
diagnosed glioblastoma. However, the drug could be useful in individual patients with large tumours who are 
highly symptomatic and resistant to steroids, who might otherwise not tolerate radiotherapy. 
 
Tumour-treating fields represent a novel treatment modality designed to deliver alternating electrical fields to 
the brain. An open-label randomised phase III trial67 of tumour-treating fields added to standard maintenance 
temozolomide chemotherapy in newly diagnosed patients with glioblastoma was terminated early when an 
interim analysis of the first cohort of 315 randomised patients was analysed and longer overall survival was 
reported in patients treated with tumour-treating fields added to standard maintenance temozolomide 
chemotherapy compared with patients treated with standard maintenance temozolomide chemotherapy 
alone (hazard ratio 0·74, 95% CI 0·56–0·98, log-rank p=0·03). Analysis68 of the full cohort of 695 patients 
showed that both progression free survival and overall survival were longer in patients treated with tumour-
treating fields added to standard maintenance temozolomide chemotherapy compared with patients treated 
with standard maintenance temozolomide chemotherapy alone.68 
Questions about the mode of action, interpretation of data, and effect on quality of life have been 
raised,69 and the role and cost-effectiveness of tumour-treating fields in the treatment of newly diagnosed 
glioblastoma remain to be defined.70 
 
Standards of care for patients with recurrent glioblastoma are not well defined. Clinical decision making is 
influenced by previous treatment, age, Karnofsky performance score, and patterns of progression. Second 
surgery is considered for 20–30% of patients in clinical practice, commonly for symptomatic but circumscribed 
lesions and when the interval since the preceding surgery exceeds 6 months. Second surgery might also be 
considered in the case of early progression in symptomatic patients in whom initial surgery was not adequate. 
The effect of second surgery on survival might be limited to patients who are candidates for gross total 
resection of enhancing tumour,71 but prospective data from randomised trials are not available to confirm a 
role for second surgery. The efficacy of re-irradiation and the value of aminoacid PET for target delineation 
remain debated. Fractionation depends on tumour size. Doses of conventional or near conventional 
fractionation have been tested, but also higher doses per fraction of 5–6 Gy using stereotactic 
hypofractionated radiotherapy to a total dose of 30–36 Gy, or even radiosurgery with a single dose of 15–20 
Gy, have acceptable toxicity.72 Yet, no relevant monotherapy efficacy (progression-free survival rate of 3·8% at 
6 months) was demonstrated in a larger randomised trial at 18 fractions of 2 Gy.73 
 
The main systemic treatment options at progression after concomitant and maintenance temozolomide 
chemotherapy and radiotherapy in Europe are nitrosoureas, temozolomide rechallenge, and bevacizumab. 
Lomustine is increasingly considered standard treatment because no other treatment has yielded better 
results in a controlled clinical trial, but progression-free survival rates at 6 months are only in the range of 15–
25% with lomustine therapy.74,75 Similar results have been reported with alternative dosing regimens of 
temozolomide,76 but activity is probably limited to patients with tumours with MGMTpromoter 
methylation.77,78 The BR12 trial44 showed no benefit of dose-intensified temozolomide over standard-dose 
temozolomide in temozolomide-naive patients with malignant glioma, but does not provide information 
about the value of temozolomide rechallenge for patients pre-treated with temozolomide. Therefore, no 
reason exists to administer dose-intensified temozolomide to patients who are temozolomide-naive. Whether 
dose-intensified regimens are superior to standard-dosed temozolomide in recurrent glioblastoma after a 
temozolomide-free interval, remains undetermined. 
 
Bevacizumab is approved for recurrent glioblastoma in various countries, but not in the European Union, on 
the basis of two phase 2 studies79,80 which noted that the proportion of patients with a response is around 
30% and the length of progression-free survival and overall survival compare favourably with historical 
controls. The value of bevacizumab in clinical practice is widely accepted because of transient symptom 
control and the option for steroid sparing in a subset of patients.79,80 The BELOB trial77 showed that overall 
survival at 9 months might be longer in patients treated with bevacizumab and lomustine than that in patients 
treated with either drug alone, but the EORTC 26101 phase III trial78 did not confirm that the combination of 
bevacizumab and lomustine increased overall survival compared with lomustine alone. No other active 
combination partner for bevacizumab has been identified. Tumour-treating fields were not superior to best 
physician's choice in a randomised phase III trial.81 
 
Diffuse midline glioma 
Diffuse midline glioma, histone H3-K27M mutant, is a new tumour entity that has been classified as WHO 
grade IV. The tumour includes most brainstem, thalamic, and spinal diffuse gliomas in children and adults. 
Surgical options are limited, treatment beyond radiotherapy is not established, and the prognosis is poor. 
Traditionally, treatment has followed the standards of care for gliomas of the same WHO grade in other 
anatomical locations. 
 
Oligodendroglioma 
Oligodendrogliomas are defined as IDH-mutant and 1p/19q-codeleted grade II tumours by the 2016 WHO 
classification.1 In rare cases, without conclusive data on IDH mutation and 1p/19q codeletion status, tumours 
are classified as oligodendroglioma, not otherwise specified. The diagnosis of oligoastrocytoma is discouraged 
in the new WHO classification, which states that only exceptional cases that cannot be conclusively tested for 
IDH mutation and 1p/19q codeletion that show a mixed oligoastrocytic histology can still be classified as 
oligoastrocytoma, not otherwise specified.1 Surgery is the primary treatment for IDH-mutant and 1p/19q-
codeleted oligodendroglioma. Although contemporary trials addressing this issue are not available, watch-
and-wait strategies are justified in patients with macroscopically complete resection, and also in younger 
patients (aged <40 years) with incomplete resection if the tumour has not already caused neurological deficits 
beyond symptomatic epilepsy. The standard treatment for oligodendrogliomas is radiotherapy followed by 
procarbazine, lomustine, and vincristine chemotherapy if further treatment beyond surgery is considered 
necessary.15 
 
Anaplastic oligodendroglioma 
Anaplastic oligodendrogliomas are defined as IDH-mutant and 1p/19q-codeleted grade III tumours by the 
2016 WHO classification;1 not otherwise specified is only assigned if conclusive molecular information is 
absent. The diagnosis of anaplastic oligoastrocytoma is discouraged and no longer applicable when tumours 
are successfully tested for IDH mutation and 1p/19q codeletion. Extent of resection is a prognostic 
factor.43,82 The role of grading (II versus III) in IDH-mutant, 1p/19q-codeleted gliomas remains controversial. 
Accordingly, watch-and-wait strategies after complete resection might be considered even with WHO grade III 
tumours in younger patients, notably after gross total resection and in the absence of neurological deficits. 
Two large randomised clinical trials—EORTC 2695122 and RTOG 940223—showed that in a subset of patients 
with 1p/19q-codeleted oligodendroglial tumours, patients treated with procarbazine, lomustine, and 
vincristine chemotherapy, either before or after radiotherapy, in first-line treatment had longer overall 
survival compared with patients treated with radiotherapy alone. Although these results stem from analyses 
of small patient cohorts, both studies show similar results, validating each other and defining the current 
standard of care. Important questions remain: whether long-term survivors treated with radiotherapy plus 
procarbazine, lomustine, and vincristine experience preserved cognitive function and quality of life,83 and 
whether the longer overall survival could be achieved with concomitant and maintenance temozolomide plus 
radiotherapy compared with radiotherapy alone. Long-term results from the NOA-04 trial35,43 show that 
chemotherapy alone is not superior to radiotherapy alone in IDH-mutant and 1p/19q-codeleted anaplastic 
oligodendroglioma or IDH-mutant anaplastic astrocytoma, indicating that chemotherapy with alkylating drugs 
alone is unlikely to achieve the same outcome as radiotherapy combined with procarbazine, lomustine, and 
vincristine. Whether the efficacy of concomitant and maintenance temozolomide plus radiotherapy treatment 
is similar to radiotherapy followed by procarbazine, lomustine, and vincristine is explored in the modified 
CODEL trial (NCT00887146). 
Treatment at progression is influenced by response to first-line treatment. In cases in which radiotherapy and 
alkylating drugs are not treatment options because patients have not responded, or because of intolerance, 
bevacizumab has been used,84,85 but the drug is of unknown efficacy as controlled studies are lacking.84,85 No 
evidence exists for the use of combined treatment with bevacizumab and cytotoxic drugs in this setting. 
 
Other astrocytic tumours 
Pilocytic astrocytoma and its variant, pilomyxoid astrocytoma, are rare tumours in adults and are commonly 
cured by surgery alone. Radiotherapy is only indicated at progression when surgical options no longer exist. 
Pilocytic astrocytoma of the optic nerve can be associated with neurofibromatosis type I and cannot be 
resected unless visual function has already been lost. These lesions often do not require treatment. 
 
Subependymal giant cell astrocytomas are WHO grade I lesions associated with tuberous sclerosis and might 
respond to mTOR inhibition if treatment after surgery is required.86 
 
Pleomorphic xanthoastrocytoma (WHO grade II) occurs predominantly in children and young adults and about 
70% of tumours have the BRAFV600E mutation.1 This tumour should be resected and patients may be followed 
up by the use of a watch-and-wait strategy after gross total resection. Anaplastic pleomorphic 
xanthoastrocytoma (WHO grade III) should probably be managed with postoperative radiotherapy and not 
with a watch-and-wait strategy. In recurrent anaplastic pleomorphic astrocytoma, BRAF inhibitors, such as 
vemurafenib, seem to have limited activity.87 
 
Coordination of care and outlook 
Diagnosis and management plans for patients with glioma should follow multidisciplinary tumour board 
recommendations throughout the disease course. Tumour boards composed of experts from different 
specialties are a forum in which to discuss which procedures can be done locally, which are better done at a 
specialised centre, which are appropriate for inpatient versus outpatient settings, and which 
neurorehabilitation measures are useful. Local and national guidelines and upcoming EANO guidelines provide 
further guidance. Guidelines reflect knowledge and consensus at a specific timepoint. The EANO website will 
report future updates on this guideline. 
 
Search strategy and selection criteria 
This guideline was prepared by a task force nominated by the Executive Board of the European Association for 
Neuro-Oncology (EANO) in cooperation with the Brain Tumor Group of the European Organisation for 
Research and Treatment of Cancer in 2016. The task force represents the disciplines involved in the diagnosis 
and care of patients with glioma and reflects the multinational character of EANO. We used PubMed and the 
search terms “glioma”, “anaplastic”, “astrocytoma”, “oligodendroglioma”, “glioblastoma”, “trial”, “clinical”, 
“radiotherapy” and “chemotherapy” to retrieve references for articles published in English between Jan 1, 
2001, and July 31, 2016. We also identified publications through searches of the authors' own files. Data 
available only in Abstract form were only included if we felt they had the potential to change practice. The 
definitive reference list included articles deemed relevant to the broad scope of this guideline. 
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